The effect of parturient height on the median effective dose of intrathecally administered ropivacaine

Xiangdi Yu, Fangxiang Zhang, Xiangdi Yu, Fangxiang Zhang

Abstract

Background: Pain during cesarean delivery is one of the more common reasons for a successful medicolegal claim. However, creating an extensive block area can result in hypotension, so determining the precise dose of local anesthetic is critical.

Objectives: Investigate effects of parturient height on the median effective dose (ED50) of intrathecally-administered ropivacaine.

Design: Prospective cross-sectional analytic study.

Setting: Anesthesiology department in a provinicial hospital in China.

Methods: Parturients undergoing cesarean delivery under combined spinal and epidural anesthesia were stratified according to height as follows: 150 cm to 155 cm, 156 cm to 160 cm, 161 cm to 165 cm and 166 cm to 170 cm. The spinal component of the anesthetic was established by bolus administration of up-and-down doses of 0.75% plain ropivacaine as determined by the Dixon method. The initial dose of ropivacaine was 5.79 mg and the testing interval dose change was set at 0.75 mg. The block height for the first cold feeling at T5 was considered satisfactory anesthesia.

Main outcome measures: ED50 values and vasopressor requirements, nausea, vomiting and shivering.

Results: In 120 parturients, the ED50 for satisfactory block height using intrathecal ropivacaine was 5.92 mg (95% confidence interval[CI] 5.02-6.86 mg) patients of 150 to 155 cm in height; 6.52 mg (95% CI 5.45-7.65 mg) in 156 cm to 160 cm; 7.49 mg (95%CI 6.83-8.25 mg) in 161 cm to 165 cm; 8.35 mg (95%CI 7.55-9.23 mg) in 166 to 170 cm. The ED50 of ropivacaine increased with increasing height of the subject. There were no significant differences in incidence of hypotension, vasopressor requirements, nausea, vomiting and shivering.

Conclusion: The ED50 of intrathecal ropivacaine using sensitivity to cold sensation increased with parturient height, indicating that dose may be determined in part by height.

Limitation: The ED95 rather than the ED50 for spinal anesthesia is more useful clinically. We did not control for the effect of weight on the dose of local anesthetic. Factors such as baricity, volume, concentration injected, temperature of the solution, and viscosity can affect intrathecal spread of the local anesthetics and block quality.

Conflict of interest statement

Conflict of interest

The authors report no conflict of interest.

Figures

Figure 1
Figure 1
Effect of height on the median effective dose for the block height arrived at T5 using cold sensation. Subject response (filled circle) to sensory block (to cold sensation) at T5 at dose of intrathecal ropivacaine (numbers are dose of ropivacaine in mg). Arrow indicates the mean dose for the height group.
Figure 2
Figure 2
Mean effective dose (ED50; 95% confidence interval) for the block height arrived at T5 using cold in a standardized manner for each of 4 height groups, from 150 to 155 cm to 165 to 170 cm.

References

    1. Bogod D. Medicolegal implications. In: Reynolds F, editor. Regional Analgesia in Obstetrics; a Millennium Update. London: Springer; 2000. pp. 371–80.
    1. Corke BC, Datta S, Ostheimer GW, Weiss JB, Alper MH. Spinal anaethesia for caerarean section. The influence of hypotension on neonatal outcome. Anaesthesia. 1982;37:658–62.
    1. Marx GF, Cosmi EV, Wollman SB. Biochemical status and clinical condition of mother and infant at cesarean section. Anesth Analg. 1969;48:986–94.
    1. Danelli G, Zangrillo A, Nucera D, Giorqi E, Faneli G, Senatore R, Casati A. The minimum effective dose of 0.5% hyperbaric spinal bupivacaine for cesarean section. Minerva Anestesiol. 2001;67:573–7.
    1. Huffnagle SL, Norris MC, Leighton BL, Arkoosh VA, Elgart RL, Huffnagle HJ. Do patient variables influence the subarachnoid spread of hyperbaric lidocaine in the postpartum patient? Reg Anesth. 1994;19:330–4.
    1. Norris MC. Height, weight, and the spread of subarachnoid hyperbaric bupivacaine in the term parturient. Anesth Analg. 1988;67:555–8.
    1. Bourne TM, deMelo AE, Bastianpillai BA, May AE. A survey of how British obstetric anaesthetists test regional anaesthesia before caesarean section. Anaesthesia. 1997;52:901–3.
    1. Ousley R, Egan C, Dowling K, Cyna AM. Assessment of block height for satisfactory spinal anaesthesia for caesarean section. Anaesthesia. 2012;67:1356–1363.
    1. Camorcia M, Capogna G, Berritta C, Columb MO. The relative potencies for motor block after intrathecal ropivacaine, levobupivacaine, and bupivacaine. Anesth Analg. 2007;104:904–7.
    1. Columb MO, D’Angelo R. Up-down studies: responding to dosing! Int J Obstet Anesth. 2006;15:129–36.
    1. Dixon WJ, Massey FJ. Introduction to Statistical Analysis. 4rd ed. New York, NY: McGraw-Hill; 1983.
    1. Paul M, Fisher DM. Are estimates of MAC reliable? Anesthesiology. 2001;95:1362–70.
    1. Pace NL, Statt M, Stylianou MP. Advances and limitations of up and down methodology. Anesthesiology. 2007;107:144–52.
    1. Harten JM, Boyne I, Hannah P, Varveris D, Brown A. Effects of a height and weight adjusted dose of local anesthetic for spinal anaesthesia for elective Caesarean section. Anaesthesia. 2005;60:348–53.
    1. Pargger H, Hampl KF, Aeschbach A, Paganoni R, Schneider MC. Combined effect of patient variables on sensory level after spinal 0.5% plain bupivacaine. Acta Anaesthesiol Scand. 1998;42:430–4.
    1. Norris MC. Height, weight, and the spread of subarachnoid hyperbaric bupivacaine in the term parturient. Anesth Analg. 1998;67:555–8.
    1. Norris MC. Patient variables and the subarachnoid spread of hyperbaric bupivacaine in term parturient. Anesthesiology. 1990;72:478–82.
    1. Do patient variables influence the subarachnoid spread of hyperbaric lidocaine in the postpartum patient? Reg Anesth. 1994;19:330–4.
    1. Mc Culloch WJ, Littlewood DG. Influence of obesity on spinal analgesia with isobaric 0.5% bupivacaine. British Journal of Anaesthesia. 1986;58:610–4.
    1. Hocking G, Wildsmith JA. Intrathecal drug spread. Br J Anaesth. 2004;93:568–78.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe